New clinical paper
Today saw the publication of a new clinical paper supporting the benefits of BeaT-2 as a food-based solution to the food related challenges presented by Type 2 diabetes. Specifically the study demonstrated:
- Improvement in Glycemic Control:
- The BeaT-2 test group exhibited significant improvements in HbA1c, fasting glucose, and insulin levels compared to the placebo group.
- Improvement in Insulin Sensitivity:
- The study indicated that BeaT-2 may improve insulin sensitivity, as reflected in the reduction of HOMA-IR (Homeostasis Model Assessment of Insulin Resistance).
- Inflammation reduced:
- The BeaT-2 group showed a decrease in hsCRP (high-sensitivity C-reactive protein), a marker of chronic systemic inflammation.
- Impacting positively on other metabolic parameters:
- The study also observed positive changes in lipid profiles and other parameters of metabolic syndrome, suggesting a broader positive impact on cardiometabolic health.
The work was carried out by Prof. Dr. Andreas Pfützner and his team. The study was funded by de Faire Medical AB. The full publication can be found here:
For more information, please get in touch:
Contact@defairemedical.com / Pressoffice@defairemedical.com
De Faire Medical consists of de Faire Medical AB (headquartered in Uppsala, Sweden) and its subsidiaries. De Faire Medical is the leading developer of fermented rice bran derived food supplements and other products in the consumer healthcare industry, shaping the future of health through innovation in nutritional science. Our brands are available in more than 50 countries and include category leaders such as Myrkl, Adileum and BeaT-2.
